Baojin Hua

Dr. Baojin Hua


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
WLWeidong Li
Weidong Li
SSShakir M. Saud
Shakir M. Saud
MYMatthew R. Young
Matthew R. Young
GCGuohong Chen
Guohong Chen
BHBaojin Hua
Baojin Hua
Targeting AMPK for cancer prevention and treatment

16 November 2016 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
QGQiujun Guo
Qiujun Guo
ZJZhichao Jin
Zhichao Jin
YYYuan Yuan
Yuan Yuan
RLRui Liu
Rui Liu
TXTao Xu
Tao Xu
BHBaojin Hua
Baojin Hua
The majority of basic and clinical studies have shown a protumor function of tumor-associated macrophages (TAMs), which represent a large proportion of matrix cells. TAMs promote tumorigenesis, and their number is related to the malignancy degree and poor prognosis of many kinds of tumors. Macrophage plasticity makes it possible to change the tumor microenvironment and remodel antitumor immunity during cancer immunotherapy. Increasing numbers of studies have revealed the effects of TAMs on the tumor microenvironment, for example, via promotion of tumor growth and tumorigenesis and through an increase in the number of cancer stem cells or via facilitation of angiogenesis, lymphangiogenesis, and metastasis. Investigators also proposed tumor-immunological treatments targeting TAMs by inhibiting TAM recruitment and differentiation, by regulating TAM polarization, and by blocking factors and pathways associated with the protumor function of TAMs. This comprehensive review presents recent research on TAMs in relation to prediction of poor outcomes, remodeling of the tumor immune microenvironment, and immunological targeted therapies.

26 April 2015 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
WLWeidong Li
Weidong Li
SSShakir M. Saud
Shakir M. Saud
MYMatthew R. Young
Matthew R. Young
NCNancy H. Colburn
Nancy H. Colburn
BHBaojin Hua
Baojin Hua

12 October 2016 in BioMed Research International
Verified
Journal Article
Open access
PDF file
QGQiujun Guo
Qiujun Guo
YYYuan Yuan
Yuan Yuan
ZJZhichao Jin
Zhichao Jin
TXTao Xu
Tao Xu
YGYebo Gao
Yebo Gao
BHBaojin Hua
Baojin Hua
Background. Vasculogenic mimicry can promote tumor growth and metastasis. This article is aimed at conducting a systematic meta-analysis to explore the clinicopathological and prognostic significance of vasculogenic mimicry and gastric cancer.Methods. We searched Pubmed, EMBASE, Cochrane Library, China National Knowledge Infrastructure, and the VIP and Wanfang Database for eligible studies. We manually searched for printed journals and relevant textbooks. Subgroups analyses were performed based on the region, manuscript quality, methods of vasculogenic mimicry identification, pathology, and number of patients.Results. Nine studies with 997 patients were included in this meta-analysis. A significant association was observed between vasculogenic mimicry-positive patients and those with gastric cancer with poor overall survival (hazard ratio = 2.24, 95% confidence interval: 1.45–3.47), poor pathological grading, high tumor node metastasis clinical stage, lymph node metastasis, deep tumor invasion, and distant metastasis.Conclusions. Vasculogenic mimicry is associated with a poor prognosis in patients with gastric cancer in China. Clinical studies with large samples are needed worldwide and standardized protocols should be adopted in the future to achieve a better understanding of the relationship between gastric cancer and vasculogenic mimicry.

1 January 2016 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
TXTao Xu
Tao Xu
ZJZhichao Jin
Zhichao Jin
YYYuan Yuan
Yuan Yuan
HWHuamin Wei
Huamin Wei
XXXinyao Xu
Xinyao Xu
BHBaojin Hua
Baojin Hua
Objective. To evaluate ginsenoside Rg3 combined with chemotherapy for non‐small‐cell lung cancer (NSCLC) treatment, in a meta‐analysis. Materials and Methods. We searched PubMed, EMBASE, the Cochrane Library, the China National Knowledge Infrastructure, and the VIP and Wanfang databases for eligible studies. We manually searched for printed journals and relevant textbooks. Statistical analyses were performed with Revman 5.3 and STATA 14.0 software packages. Results. Twenty studies were included. Ginsenoside Rg3 combined with chemotherapy could enhance response, improve disease control, prolong overall survival, improve patient quality of life, reduce leucocyte count decrease due to chemotherapy, reduce vascular endothelial growth factor expression in peripheral blood, and increase CD4/CD8 T cell ratio. Conclusion. Ginsenoside Rg3 combined with chemotherapy may enhance short‐term efficacy and overall survival, alleviate treatment‐induced side effects, reduce vascular endothelial growth factor expression, increase CD4/CD8 T cell ratio, and serve as a potential therapeutic regimen for NSCLC. However, considering the limitations, the conclusion should be interpreted carefully, and these results need to be confirmed by more high‐quality trials.

16 May 2017 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
HWHai-Long Wang
Hai-Long Wang
YZYong-Ming Zhou
Yong-Ming Zhou
GZGuang-Zhao Zhu
Guang-Zhao Zhu
ZYZhu Yang
Zhu Yang
BHBaojin Hua
Baojin Hua